Group 1 - The core point of the article is that Weiguang Biological (002880) has submitted an application for a private placement of shares, which has been accepted by the Shenzhen Stock Exchange [1] - The company plans to issue no more than 45.36 million shares [1] - The expected fundraising amount is 1.5 billion yuan [1] - The sponsor for this issuance is Guosen Securities Co., Ltd. [1]

Core Points - Shenzhen Wego Biological Products Co., Ltd. has received acceptance from the Shenzhen Stock Exchange for its application to issue A-shares to specific investors [1] - The application documents submitted by the company were found to be complete and were accepted by the Shenzhen Stock Exchange [1] - The issuance of A-shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating uncertainty in the final approval process [1] Summary by Sections - **Company Announcement** - The company announced on October 10, 2025, that it received a notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific issuance of A-shares [1] - The board of directors ensures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1] - **Regulatory Process** - The acceptance of the application is a preliminary step, and the final decision depends on further review and approval by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - The company will continue to fulfill its information disclosure obligations based on the progress of this matter [1]

Core Viewpoint - The company, Weiguang Biological, has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific investors, aiming to raise a total of 1.5 billion yuan [1] Fundraising Details - The total amount to be raised, including issuance costs, is 1.5 billion yuan [1] - Out of the total, 1.2 billion yuan will be allocated to the Weiguang Biological Intelligent Industry Base project [1] - The remaining 300 million yuan will be used to supplement working capital [1]

Core Viewpoint - Shenzhen Wego Biological Products Co., Ltd. has received notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific object issuance of A-shares, indicating a step forward in its capital raising efforts [1] Group 1: Company Announcement - The company announced that it received a notice from the Shenzhen Stock Exchange on October 10, 2025, regarding the acceptance of its application for issuing shares to specific investors [1] - The application documents submitted by the company were deemed complete by the Shenzhen Stock Exchange, leading to the decision to accept the application [1] - The issuance of A-shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating that the process is not yet finalized [1] Group 2: Regulatory Process - The final approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission remains uncertain, highlighting the regulatory hurdles that the company must navigate [1] - The company commits to timely information disclosure based on the progress of this matter, emphasizing transparency in its operations [1]

Group 1 - The company, Shenzhen Weiguang Biological Products Co., Ltd., has received a notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific object issuance of A-shares [1] - The application documents submitted by the company have been verified as complete by the Shenzhen Stock Exchange, which has decided to accept the application [1] - The issuance of A-shares is subject to approval by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission, indicating uncertainty regarding the final approval and timeline [1]

Core Viewpoint - The company has received a notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance, which is subject to further approval and registration by regulatory authorities [1] Group 1 - The company announced that on October 10, 2025, it received a notice from the Shenzhen Stock Exchange about the acceptance of its application for a specific stock issuance [1] - The issuance of A-shares to specific investors requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1] - There is uncertainty regarding the approval process and the time required for it, and the company will fulfill its information disclosure obligations based on the progress [1]

证券代码:002880 证券简称:卫光生物 公告编号:2025-045 公司本次向特定对象发行A股股票事项尚需深圳证券交易所审核通过，并获 得中国证券监督管理委员会同意注册后方可实施。最终能否通过深圳证券交易所 审核并获得中国证券监督管理委员会同意注册的决定及所需时间仍存在不确定 性。公司将根据该事项进展情况及时履行信息披露义务，敬请广大投资者谨慎决 策，注意投资风险。 特此公告。 深圳市卫光生物制品股份有限公司董事会 2025年10月13日 获得深圳证券交易所受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年10月10日收到 深圳证券交易所出具的《关于受理深圳市卫光生物制品股份有限公司向特定对象 发行股票申请文件的通知》（深证上审〔2025〕182号）。深圳证券交易所对公 司报送的向特定对象发行股票的申请文件进行了核对，认为申请文件齐备，决定 予以受理。 深圳市卫光生物制品股份有限公司 关于 2025 年度向特定对象发行 A 股股票申请 ...

深圳市卫光生物制品股份有限公司 向特定对象发行 A 股股票募集说明书 （注册地址：深圳市罗湖区红岭中路 1012 号国信证券大厦 16-26 层） 二〇二五年九月 股票简称：卫光生物 股票代码：002880 保荐机构（主承销商） 深圳市卫光生物制品股份有限公司 募集说明书 声明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所做的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性做出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益做出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-1 深圳市卫光生物制品股份有限公司 募集 ...

国信证券股份有限公司关于 深圳市卫光生物制品股份有限公司 主板向特定对象发行 A 股股票的 上市保荐书 保荐人（主承销商） （注册地址：深圳市红岭中路 1012 号国信证券大厦 16-26 层） 保荐机构声明 本保荐机构及所指定的两名保荐代表人均是根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上 市公司证券发行注册管理办法》（以下简称《注册管理办法》）等法律法规和中国 证券监督管理委员会（以下简称中国证监会）及深圳证券交易所的有关规定，诚 实守信，勤勉尽责，严格按照依法制订的业务规则和行业自律规范出具本上市保 荐书，并保证所出具的文件真实、准确、完整。 3-3-1 深圳证券交易所： 深圳市卫光生物制品股份有限公司（以下简称卫光生物、发行人、公司）拟 申请向特定对象发行股票。国信证券股份有限公司（以下简称国信证券、保荐机 构）认为发行人符合《公司法》《证券法》《注册管理办法》以及《深圳证券交易 所股票上市规则》（以下简称《上市规则》）等法律、法规和规范性文件的规定， 同意向贵所保荐卫光生物申请向特定对象发行股票。现将有关情况报告如下： 一、发行人基本情况 ...

国信证券股份有限公司关于 深圳市卫光生物制品股份有限公司 主板向特定对象发行 A 股股票的 发行保荐书 保荐人（主承销商） （注册地址：深圳市红岭中路 1012 号国信证券大厦 16-26 层） 保荐机构声明 本保荐机构及所指定的两名保荐代表人均是根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上 市公司证券发行注册管理办法》（以下简称《注册管理办法》）等有关法律、法规 和中国证券监督管理委员会（以下简称中国证监会）的有关规定，诚实守信，勤 勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具本发行保 荐书，并保证所出具的文件真实、准确、完整。 3-1-1 第一节 本次证券发行基本情况 一、保荐代表人情况 赖聪聪先生：投资银行事业部业务董事，管理学硕士，保荐代表人。2010 年开始从事投资银行工作，曾参与广西城投企业债项目及重庆黔江城投（二期） 企业债项目、苏垦农发（601952.SH）首发项目、星河生物（300143.SZ）2016 年度重大资产重组项目等，曾担任苏垦农发（601952.SH）首发项目现场负责人、 星河生物（300143.SZ ...